AKT1 and lung carcinoma: Liu et al. revealed that treatment with exosomes released by EGFR TKI-resistant lung cancer cells resulted in the acquisition of resistance in TKI-sensitive cells via phosphoinositide 3-kinase (PI3K)/AKT signaling pathway activation, suggesting a potential contribution of exosomes to the emergence of TKI resistance [143].